Understanding MF/SS

CTCL includes distinct lymphoma subtypes. The staging and treatment tools here focus on mycosis fungoides (MF) and Sézary syndrome (SS); they should not be applied to all cutaneous lymphomas.

ISCL/USCLC/EORTC staging update (2022), Table 2

Diagnosis remains a clinical and pathology assessment

MF may resemble inflammatory skin disease. Patch, plaque and tumor describe appearances, not an inevitable sequence. An uncertain biopsy may require follow-up or further sampling. A clonality result alone does not settle the diagnosis.

International expert panel (2022): suspected early MF Review a biopsy report category

Staging is separate from diagnosis

MF/SS stage combines skin, nodal, visceral and blood categories. Skin extent alone is insufficient. Erythroderma or a B2 blood category alone does not establish Sézary syndrome.

ISCL/USCLC/EORTC staging update (2022), Table 2 Open MF/SS staging

Treatment and outlook

Discuss treatment and prognosis using the confirmed subtype, extent and individual circumstances. This app does not predict an individual survival time.

Treatment guidance and source limitations

App convention: risk bands and report categories organize the workflow. They are not validated diagnostic classifications. Clinical sources reviewed 23 September 2026.